Vertex casually drops Orkambi revenue slowdown, creating

Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

S-1/A

S-1

Dropbox Stock: Slowing Growth? So What! (NASDAQ:DBX)

Vertex casually drops Orkambi revenue slowdown, creating 'unnecessary drama' for investors

SEC Filing – Royalty Pharma

The Optimism Ecosystem has Flourished upon Numerous Positive News – BingX Blog

SEC Filing – Royalty Pharma

February 2016 DC Beacon by The Beacon Newspapers - Issuu

March 2016 Baltimore Beacon by The Beacon Newspapers - Issuu

There's A Dark Cloud On Dropbox's Horizon

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

Webfonts: Making Wikimedia projects readable for everyone